10:07 AM EDT, 07/21/2025 (MT Newswires) -- Tiziana Life Sciences ( TLSA ) said Monday that its product candidate intranasal foralumab demonstrated "profound immune modulatory effects" in a patient with moderate Alzheimer's disease based on white blood cell analysis before and after treatment.

"In an unexpected discovery, the analysis revealed an increase in phagocytosis markers in classical monocytes, suggesting that nasal foralumab may enhance their ability to clear amyloid plaques," Tiziana said.

The company said intranasal foralumab well tolerated without reported side effects and the patient has elected to continue treatment for six more months.

Shares of Tiziana Life Sciences ( TLSA ) were 1.2% higher in recent Monday trading.

Price: 1.60, Change: +0.05, Percent Change: +3.23